BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551 AND Treatment
15 results:

  • 1. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
    Merseburger AS; Attard G; Åström L; Matveev VB; Bracarda S; Esen A; Feyerabend S; Senkus E; López-Brea Piqueras M; Boysen G; Gourgioti G; Martins K; Chowdhury S
    Lancet Oncol; 2022 Nov; 23(11):1398-1408. PubMed ID: 36265504
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?
    Eggers H; Schünemann C; Grünwald V; Rudolph L; Tiemann ML; Reuter C; Anders-Meyn MF; Ganser A; Ivanyi P
    World J Urol; 2022 Oct; 40(10):2489-2497. PubMed ID: 35916904
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Selective Cytotoxicity of Portuguese Propolis Ethyl Acetate Fraction towards Renal Cancer Cells.
    Freitas AS; Costa M; Pontes O; Seidel V; Proença F; Cardoso SM; Oliveira R; Baltazar F; Almeida-Aguiar C
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807247
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes.
    Cao P; Wu JY; Zhang JD; Sun ZJ; Zheng X; Yu BZ; Cao HY; Zhang FL; Gao ZH; Wang W
    BMC Cancer; 2022 Jun; 22(1):691. PubMed ID: 35739510
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Mutant CDKN2A regulates P16/p14 expression by alternative splicing in renal cell carcinoma metastasis.
    Sun Q; Chen S; Hou Y; Wen X; Teng X; Zhang H; Lai C; Lai M
    Pathol Res Pract; 2021 Jul; 223():153453. PubMed ID: 34022680
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma.
    Kato T; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya YU; Wang C; Hatano K; Kawashima A; Ujike T; Kawasaki K; Morii E; Gotoh K; Eguchi H; Kiyotani K; Fujita K; Nonomura N; Uemura M
    Anticancer Res; 2020 Sep; 40(9):4875-4883. PubMed ID: 32878775
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Transition from open partial nephrectomy directly to robotic surgery: experience of a single surgeon to achieve "TRIFECTA".
    Castilho TML; Lemos GC; Cha JD; Colombo JR; Claros OR; Lemos MB; Carneiro A
    Int Braz J Urol; 2020; 46(5):814-821. PubMed ID: 32648421
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
    de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
    Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Addressable Peptide Self-Assembly on the Cancer Cell Membrane for Sensitizing Chemotherapy of Renal Cell Carcinoma.
    Wang Z; An HW; Hou D; Wang M; Zeng X; Zheng R; Wang L; Wang K; Wang H; Xu W
    Adv Mater; 2019 Mar; 31(11):e1807175. PubMed ID: 30663139
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
    Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
    Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
    Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms' tumor onset.
    Maschietto M; Trapé AP; Piccoli FS; Ricca TI; Dias AA; Coudry RA; Galante PA; Torres C; Fahhan L; Lourenço S; Grundy PE; de Camargo B; de Souza S; Neves EJ; Soares FA; Brentani H; Carraro DM
    Cell Death Dis; 2011 Nov; 2(11):e224. PubMed ID: 22048167
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
    Okuno T; Tamura T; Yamamori M; Chayahara N; Yamada T; Miki I; Okamura N; Kadowaki Y; Shirasaka D; Aoyama N; Nakamura T; Okumura K; Azuma T; Kasuga M; Sakaeda T
    Am J Clin Oncol; 2007 Jun; 30(3):252-7. PubMed ID: 17551301
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A pituitary gene encodes a protein that produces differentiation of breast and prostate cancer cells.
    Platica M; Ivan E; Holland JF; Ionescu A; Chen S; Mandeli J; Unger PD; Platica O
    Proc Natl Acad Sci U S A; 2004 Feb; 101(6):1560-5. PubMed ID: 14745005
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG.
    Miller EB; Eure GR; Schellhammer PF
    Urology; 1993 Jul; 42(1):26-30. PubMed ID: 8328123
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.